Mass General Brigham Trial Finds High Dose Vitamin D3 Fails to Reduce COVID Severity but Shows Potential Long COVID Protection

A Mass General Brigham study finds that while vitamin D doesn't stop severe COVID, it may reduce the risk of long-term symptoms like fatigue and brain fog.

By: AXL Media

Published: Mar 16, 2026, 4:31 AM EDT

Source: Information for this report was sourced from Mass General Brigham

Rigorous Testing of Vitamin D for Acute Infection

The search for effective treatments to mitigate the impact of the global pandemic led researchers at Mass General Brigham to conduct the Vitamin D for COVID-19 (VIVID) Trial. This study, one of the largest and most comprehensive randomized trials on the subject, aimed to determine if high doses of vitamin D3 could decrease the severity of acute infections or prevent transmission within households. Despite widespread interest in the supplement’s potential immune-boosting properties, the results published in The Journal of Nutrition indicate that vitamin D3 did not significantly alter the course of the initial illness or reduce the necessity for emergency medical care.

Structure and Scope of the VIVID Trial

The trial spanned multiple years and continents, including a diverse participant pool from the United States and Mongolia between 2020 and 2022. In total, 1,747 adults who recently tested positive for the virus and 277 of their household contacts were monitored. Participants followed a specific dosing protocol, receiving 9,600 IU of vitamin D3 for the first two days, followed by a daily maintenance dose of 3,200 IU. To ensure the accuracy of the findings, lead authors used statistical weighting to balance demographic factors such as age, body mass index, and race, providing a clear comparison between the treatment and placebo groups.

Clinical Outcomes and Healthcare Utilization

Over the four week observation period, the researchers tracked a wide range of health markers, including clinic visits, hospitalizations, and mortality rates. The data revealed no meaningful difference between those taking the high-dose supplement and those in the placebo group. Symptom severity remained consistent across both cohorts, and the supplement failed to provide a protective effect for household members living with infected individuals. Dr. JoAnn Manson, a senior author of the study, noted that while the primary goal of reducing acute severity was not met, the trial's rigorous design provided a definitive answer regarding vitamin D's role during the immediate infection phase.